Cullinan Therapeutics (CGEM) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

Does the media refer more to RXRX or CGEM?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 5 mentions for Cullinan Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 1.24 beat Cullinan Therapeutics' score of 0.60 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, RXRX or CGEM?

Recursion Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500.

Is RXRX or CGEM more profitable?

Cullinan Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. Cullinan Therapeutics' return on equity of -26.54% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
Cullinan Therapeutics	N/A	-26.54%	-25.32%

Does the MarketBeat Community prefer RXRX or CGEM?

Cullinan Therapeutics received 15 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 83.93% of users gave Cullinan Therapeutics an outperform vote while only 56.14% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 32 56.14%	Underperform Votes 25 43.86%
Cullinan Therapeutics	Outperform Votes 47 83.93%	Underperform Votes 9 16.07%

Do insiders and institutionals have more ownership in RXRX or CGEM?

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 7.2% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate RXRX or CGEM?

Recursion Pharmaceuticals currently has a consensus target price of $7.60, suggesting a potential upside of 85.82%. Cullinan Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 306.61%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cullinan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger earnings & valuation, RXRX or CGEM?

Cullinan Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$59.82M	27.80	-$328.07M	-$1.77	-2.31
Cullinan Therapeutics	N/A	N/A	-$153.16M	-$2.91	-2.70

Summary

Cullinan Therapeutics beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.